



MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

9/26/2020; Page 1

Suggested Formula	Chloroquine Phosphate 250 mg Oral Capsules (Powder blend, 100 x Size #1 Capsules)	FIN	F 000 437v3
-------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Chloroquine Phosphate (Diphosphate), USP	25.000	g				
Lactose (Monohydrate), NF	TBD					
Sodium Chloride, USP	As required					





Suggested Formula	Chloroquine Phosphate 250 mg Oral Capsules (Powder blend, 100 x Size #1 Capsules)	FIN	F 000 437v3
-------------------	---	-----	-------------

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible): Chloroquine phosphate

Hygroscopic (protect from moisture whenever possible): Chloroquine phosphate

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing errors and considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: <https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare>.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 795* and *USP 800*, when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All required personal protective equipment (hazardous if applicable), such as but not limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFI) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Chloroquine Phosphate 250 mg Oral Capsules (Powder blend, 100 x Size #1 Capsules)	FIN	F 000 437v3
-------------------	---	-----	-------------

SUGGESTED PREPARATION (for 100 Size #1 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Chloroquine Phosphate (Diphosphate), USP §	25.000	g			
Lactose (Monohydrate), NF	TBD				
Sodium Chloride, USP	As required				

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction	
1.	<p><u>Lactose (Monohydrate) requirements for 100 x size #1 capsules</u></p> <p>A. Calculate the amount of Lactose (Monohydrate) required for the batch. Refer to attached appendix for details.</p>
2.	<p><u>Powder preparation:</u></p> <p>A. By geometric addition, combine and mix the following ingredients together:</p> <ul style="list-style-type: none"> -Chloroquine Phosphate (Diphosphate) -Lactose (Monohydrate) (Quantity determined in appendix (I)) <p>B. Pass the above powder mixture through a 40 or 50 mesh sieve.</p> <p>C. Mix the sieved powder blend using a manual tumbler mixer to ensure homogeneity.</p>
3.	<p><u>Product transfer:</u></p> <p>Fill each of the 100 Size #1 Capsules with the powder blend (Step 2C). Close each capsule tightly.</p> <p>Clean each capsule by placing the capsules in a container filled with Sodium Chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium Chloride to pass through. Finally, roll the capsules on a cloth-covered surface.</p>
4.	<p><u>Validation technique:</u></p> <p>The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (G) + 0.250 g together.</p>
5.	<p><u>Product transfer:</u></p> <p>Transfer the final product into the specified dispensing container (see “Packaging Requirements”).</p>



Suggested Formula	Chloroquine Phosphate 250 mg Oral Capsules (Powder blend, 100 x Size #1 Capsules)	FIN	F 000 437v3
-------------------	---	-----	-------------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		Packaging Requirements	
	6 months, as per USP 795*.		Tightly closed, light-resistant capsule shells and vials.
Auxiliary Labels	1	Keep at controlled room temperature (20°C – 25°C).	6 May impair mental and/or physical ability. Use care when operating a car or machinery.
	2	Keep out of reach of children.	7 Use as directed. Do not exceed prescribed dose.
	3	Cap tightly after use.	8 Protect from light.
	4	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	9 Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	5	Keep in a dry place.	
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.		
Patient Instructions	Contact your pharmacist in the event of adverse reactions.		

* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.

REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 91.
2.	USP <795>. <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2457.
3.	Chloroquine phosphate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 2nd Edition</i> . American Pharmaceutical Association; 2000: 79.
4.	Chloroquine (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 373.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2019-2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.



Appendix	Calculating the quantity of excipient required for the batch		
----------	--	--	--

Procedure																			
1.	<p><u>Capsule filling:</u></p> <p>a. For <u>each</u> ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an <u>average</u> capsule fill weight. Also, crush and triturate the ingredient first if required in formulation.</p> <p>Plug each amount into Step 2, column B.</p>																		
2.	<p><u>Volume Percent Occupied:</u></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;"></th> <th style="width: 20%; text-align: center;">Column A Quantity Required per capsule</th> <th style="width: 20%; text-align: center;">Column B Average capsule fill weight</th> <th style="width: 20%; text-align: center;">Column C A/B x 100 equals percent filled</th> </tr> </thead> <tbody> <tr> <td>a. Chloroquine Phosphate</td> <td style="text-align: center;">0.250 g</td> <td style="text-align: center;">_____ g</td> <td style="text-align: center;">_____ %</td> </tr> <tr> <td>b. Lactose (Monohydrate)</td> <td></td> <td style="text-align: center;">_____ g</td> <td></td> </tr> <tr> <td>c. Total (add column C together)</td> <td></td> <td></td> <td style="text-align: center;">_____ % (D)</td> </tr> </tbody> </table>				Column A Quantity Required per capsule	Column B Average capsule fill weight	Column C A/B x 100 equals percent filled	a. Chloroquine Phosphate	0.250 g	_____ g	_____ %	b. Lactose (Monohydrate)		_____ g		c. Total (add column C together)			_____ % (D)
	Column A Quantity Required per capsule	Column B Average capsule fill weight	Column C A/B x 100 equals percent filled																
a. Chloroquine Phosphate	0.250 g	_____ g	_____ %																
b. Lactose (Monohydrate)		_____ g																	
c. Total (add column C together)			_____ % (D)																
3.	<p><u>Calculate the quantity of Lactose (Monohydrate) required for the batch:</u></p> <p>a. Percent of Lactose (Monohydrate) required = 100% – (D) _____ % (E)</p> <p>b. Average capsule fill weight of Lactose (Monohydrate) (from column B, Step 2b): _____ g (F)</p> <p>c. Quantity of Lactose (Monohydrate) required per capsule = [(E) ÷ 100 × (F)] _____ g (G)</p> <p>d. Total quantity of Lactose (Monohydrate) required for the batch = 100 capsules × (G) _____ g (H)</p> <p>e. Total quantity of Lactose (Monohydrate) <i>plus</i> processing error = (H) x 1.05-1.09 _____ g (I)</p>																		

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2019-2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.